

E-Mail: Information quality request seeking corrections

On Fri, Jul 24, 2009 at 3:08 PM, Paul G King <paulgkingphd@gmail.com> wrote:

From: Paul G King paulgkingphd@gmail.com
To: Secretary HHS” Kathleen.Sebelius@hhs.gov, Infoquality.aspe@hhs.gov, “Commissioner of the United States Food and Drug Administration” margaret.hamburg@fda.hhs.gov, informationquality@oc.fda.gov
Cc: “Barack Obama, President USA” <president@whitehouse.gov>, "John McHugh" <jfmchughpc@aol.com>, <Steven.Galson@hhs.gov>, <ombuds@oc.fda.gov>, <janet.woodcock@fda.hhs.gov>, <joshua.sharfstein@fda.hhs.gov>, <michael.landa@fda.hhs.gov>, <virginia.behr@fda.hhs.gov>, <douglas.throckmorton@fda.hhs.gov>, <karen.midthun@fda.hhs.gov>, <cberombudsman@fda.hhs.gov>, <sherry.lard@fda.hhs.gov>, <howard.balick@fda.hhs.gov>, “Thomas R. Frieden, MD, MPH, CDC’s Director” <txf2@cdc.gov>, <marshalyn.yearginallsopp@cdc.hhs.gov>, InfoQuality@cdc.gov, InfoQuality@nih.gov, “John O. Brennan, The White House” <info@messages.whitehouse.gov>
Bcc: <Undisclosed recipients>
Date: Fri, Jul 24, 2009 at 3:08 PM EDT
Subject: Information quality request seeking corrections

Dear Madam Secretary Kathleen Sebelius and FDA Commissioner Margaret A. Hamburg,

RE: Information Quality Request for Corrections of the web page: “Thimerosal in Vaccines Questions and Answers” found at:

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm070430.htm>

*FAIR USE NOTICE: This posting may contain, or *
*have attached to it, some copyrighted(©) material *
*the use of which has not always been specifically *
*authorized by the owner or owners of the *
*copyrights. Such material is made available for *
*educational purposes, to advance the recipient's *
*understanding of human rights, democracy, scienti- *
*fic, moral, ethical, social justice and other *
*issues. It is believed that this posting is a *
*'fair use' of any such copyrighted materials as *
*provided for in Title 17 U.S.C. section 107 of the *
*US intellectual property law. This material is *
*being distributed without profit. *

Pursuant to the information provided on the HHS web page:
<http://aspe.hhs.gov/infoquality/Guidelines/ASPEinfo2.shtml#vi>,
last visited on 18 July 2009, this e-mail and the attached
review document constitute a formal information quality
request regarding the FDA web page:

“<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm070430.htm>”,

last visited on 15 July 2009.

The attached review document, "FORMAL REVIEW OF THE FDA'S: 'Thimerosal in Vaccines Questions and Answers'", provides detailed descriptions of the specific materials that need to be corrected in the aforesaid Internet web page.

In each instance where the information is believed to be in error, the attached "review" document provides the specific reasons for believing the information does not comply with OMB, HHS or ASPE guidelines and is in error, and supporting documentation and/or references to said supporting documentation when such are readily accessible to the agencies involved have been provided. For some critical issues like:

1. Teratogenicity, in **Birth Defects and Drugs in Pregnancy**.
2. No-extra-safety-margin NOAEL values, based on:
Mason MM, Cate CC, Baker J. Toxicology and Carcinogenesis of Various Chemicals Used in the Preparation of Vaccines. Clinical Toxicology, 1971; 4(2): 185-204,

"pdf" copies of the pages or documents have been provided.

To assist the agencies, those statements that appear to be knowing falsehoods are highlighted in "red" and those that are lesser distortions of factual reality are highlighted in "orange".

The general recommendation for correcting the information is to:

1. Either omit the information that is false or misleading and replace it with factual information and statements that address the declared topic, "Thimerosal in Vaccines" or
2. Publish a notice in the file listing all of the previous knowingly false information and distortions with corrections, and
3. After either 1. or 2., take disciplinary action against all those who are directly or indirectly accountable for any knowingly false information that was posted on the FDA Internet web page cited in this complaint.

In some instances, specific rewording recommendations are made to correct the false or misleading information in a manner that renders said information factually true.

With respect to the complaint and the complainant:

- In this case, the "person" submitting this complaint is CoMeD, Inc and the individual parties, including the

undersigned, who are currently engaged in litigation with the Secretary of HHS and the Commissioner of the FDA concerning the use of Thimerosal: a) in medicine, in general, and b) in vaccines and other drugs preserved with Thimerosal, in specific.

- ❑ Thus, any information error in this posted page adversely impacts the ability of the judges in U.S. Federal District Court for the District of Columbia (01:2009-cv-00015), the appropriate U.S. Federal Appeals Court and/or the U.S. Supreme Court to understand factual reality and, if the factual errors remain uncorrected, may compel the plaintiffs in that case to seek sanctions against the defendants and the defendant agencies.

Respectfully,

Paul G. King. PhD, MS
CoMeD Science Advisor
33 Hoffman Avenue
Lake Hiawatha, NJ 07034-1922
Email: drking@gti.net
Tel. 1-973-997-1321
[To whom all inquiries should be directed]

+++++

Attachments:

Posted On CoMeD Website:

090718_FormalReview_FDA's090710_ThimerosalInVaccinesQuestions&AnswersWebpgcb.pdf

Available to Researchers Upon Formal Request:

Heinonen_TopicalInText_BirthDefects&DrugsInPregnancy.pdf

AppendicesHeinonenEtAl_Birth Defects & Drugs in Pregnancy 1982 1.pdf

090719_MasonEtAl_Toxicology & Carcinogenesis of Thimerosal1a.pdf